Research analysts at StockNews.com initiated coverage on shares of Conformis (NASDAQ:CFMS – Get Rating) in a report issued on Sunday. The firm set a “hold” rating on the medical instruments supplier’s stock.
Conformis Price Performance
Shares of Conformis stock opened at $1.61 on Friday. The company’s fifty day simple moving average is $1.76 and its two-hundred day simple moving average is $1.81. Conformis has a 12-month low of $1.07 and a 12-month high of $16.66. The firm has a market cap of $12.08 million, a PE ratio of -0.23 and a beta of 1.10. The company has a quick ratio of 4.29, a current ratio of 5.63 and a debt-to-equity ratio of 0.38.
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the business. Wasatch Advisors Inc. lifted its holdings in Conformis by 9.7% in the 1st quarter. Wasatch Advisors Inc. now owns 20,030,298 shares of the medical instruments supplier’s stock worth $12,495,000 after buying an additional 1,778,054 shares during the period. Renaissance Technologies LLC raised its holdings in shares of Conformis by 4.1% during the third quarter. Renaissance Technologies LLC now owns 4,763,691 shares of the medical instruments supplier’s stock valued at $911,000 after acquiring an additional 188,200 shares in the last quarter. State Street Corp lifted its stake in Conformis by 4.2% in the first quarter. State Street Corp now owns 3,368,168 shares of the medical instruments supplier’s stock worth $2,101,000 after acquiring an additional 136,641 shares during the period. MYDA Advisors LLC bought a new stake in Conformis in the third quarter valued at $133,000. Finally, Millennium Management LLC bought a new stake in Conformis in the second quarter valued at $160,000.
About Conformis
ConforMIS, Inc is a medical technology company, which engages in the development, manufacture, and sale of joint replacement implants. It operates through the following geographical segments: United States, Germany, and Rest of the World. The firm’s products include iUni, iDuo, iTotal CR, and iTotal.
See Also
- Get a free copy of the StockNews.com research report on Conformis (CFMS)
- MarketBeat Week in Review – 4/3 – 4/7
- Costco Sales Disappoint, Markets Are Missing This Upside Driver
- First Republic Bank Is A Speculative Play, Here’s Why
- The WD-40 Company Bottoms With Reversal In Sight
- 3 Low-Cost Stock ETFs That Are Crushing It This Year
Receive News & Ratings for Conformis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conformis and related companies with MarketBeat.com's FREE daily email newsletter.
